TIRZAFIT 20

Tirzepatide is a novel dual incretin receptor agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is approved for the treatment of type 2 diabetes and has shown significant promise in weight management. By simultaneously activating GIP and GLP-1 pathways, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Its dual mechanism offers potentially superior metabolic benefits compared to selective GLP-1 receptor agonists. Tirzepatide is administered once weekly via subcutaneous injection and features a half-life suitable for weekly dosing. Clinical trials (e.g., SURPASS and SURMOUNT programs) have demonstrated substantial reductions in HbA1c and body weight. The drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).